HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): David J. Chambers Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chambers, D. J. Articles by Hearse, D. J. Search for Related Content PubMed PubMed Citation Articles by Chambers, D. J. Articles by Hearse, D. J.

Ann Thorac Surg 1999;68:1960-1966
© 1999 The Society of Thoracic Surgeons

---

I. Pathophysiology of Ischemic Reperfusion Injury

Developments in cardioprotection: "polarized" arrest as an alternative to "depolarized" arrest

^a Department of Cardiac Surgical Research/Cardiothoracic Surgery, The Rayne Institute, St. Thomas’ Hospital, London SE1 7EH, United Kingdom
^b Department of Cardiovascular Research, The Rayne Institute, St. Thomas’ Hospital, London, England, United Kingdom

Address reprint requests to Dr Chambers, Department of Cardiac Surgical Research/Cardiothoracic Surgery, The Rayne Institute, St. Thomas’ Hospital, London SE1 7EH, England
e-mail: david.chambers{at}kcl.ac.uk

Presented at the International Symposium on Myocardial Protection From Surgical Ischemic-Reperfusion Injury, Asheville, NC, Sep 21–24, 1997.

Abstract

During cardiac surgery or cardiac transplantation, the heart is subjected to varying periods of global ischemia. The heart must be protected during this ischemic period to avoid additional injury, and techniques have been developed that delay ischemic injury and minimize reperfusion injury. Almost universally, this involves using a hyperkalemic cardioplegic solution and these solutions have become the gold standard for myocardial protection for more than 20 years. Despite the extensive and continued research aimed at improving these basic hyperkalemic cardioplegic solutions, patients undergoing surgery almost invariably experience some degree of postoperative dysfunction. It is likely that this relates to the depolarizing nature of hyperkalemic solutions, which results in ionic imbalance caused by continuing transmembrane fluxes and the consequent maintenance of high energy phosphate metabolism, even during hypothermic ischemia. A potentially beneficial alternative to hyperkalemic cardioplegia is to arrest the heart in a "hyperpolarized" or "polarized" state, which maintains the membrane potential of the arrested myocardium at or near to the resting membrane potential. At these potentials, transmembrane fluxes will be minimized and there should be little metabolic demand, resulting in improved myocardial protection. Recent studies have explored these alternative concepts for myocardial protection. The use of compounds such as adenosine or potassium channel openers, which are thought to induce hyperpolarized arrest, have demonstrated improved protection after normothermic, or short periods of hypothermic, ischemia when compared to hyperkalemic (depolarized) arrest. Similarly, studies from our own laboratory, in which the sodium channel blocker, tetrodotoxin, was used to induce polarized arrest (demonstrated by direct measurement of membrane potential during ischemia) was also shown to provide better recovery of function after 5 hours of long-term hypothermic (7.5°C) storage. These promising initial studies need to be consolidated before experimental promise becomes clinical reality.

This article has been cited by other articles:

				J. Mehlsen, M. N. Kaijer, and A.-B. Mehlsen Autonomic and electrocardiographic changes in cardioinhibitory syncope Europace, January 1, 2008; 10(1): 91 - 95. [Abstract] [Full Text] [PDF]

				O. Jakobsen, S. Muller, E. Aarsaether, T. Steensrud, and D. G. Sorlie Adenosine instead of supranormal potassium in cardioplegic solution improves cardioprotection Eur. J. Cardiothorac. Surg., September 1, 2007; 32(3): 493 - 500. [Abstract] [Full Text] [PDF]

				M. D. Diodato, N. R. Shah, S. M. Prasad, S. L. Gaynor, J. S. Lawton, and R. J. Damiano Jr Donor heart preservation with pinacidil: the role of the mitochondrial KATP channel Ann. Thorac. Surg., August 1, 2004; 78(2): 620 - 627. [Abstract] [Full Text] [PDF]

				M. Scorsin, A. Mebazaa, N. A. Attar, B. Medini, J. Callebert, R. Raffoul, R. Ramadan, J. M. Maillet, A. Ruffenach, F. Simoneau, et al. Efficacy of esmolol as a myocardial protective agent during continuous retrograde blood cardioplegia J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 1022 - 1029. [Abstract] [Full Text] [PDF]

				J. Ackemann, W. Gross, M. Mory, M. Schaefer, and M.-M. Gebhard Celsior versus custodiol: early postischemic recovery after cardioplegia and ischemia at 5{degrees}C Ann. Thorac. Surg., August 1, 2002; 74(2): 522 - 529. [Abstract] [Full Text] [PDF]

				M. D. Crittenden Intraoperative metabolic monitoring of the heart: I. Clinical assessment of coronary sinus metabolites Ann. Thorac. Surg., December 1, 2001; 72(6): S2220 - 2226. [Abstract] [Full Text] [PDF]